Monday, October 10, 2016

Scholl Advance Athlete's Foot Cream





1. Name Of The Medicinal Product



Scholl Advance Athlete's Foot Cream


2. Qualitative And Quantitative Composition



Terbinafine hydrochloride 1% w/w



For excipients, see 6.1



3. Pharmaceutical Form



Cream



4. Clinical Particulars



4.1 Therapeutic Indications



The treatment of tinea pedis (athlete's foot) caused by Trichophyton (e.g. T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum) and Epidermophyton floccosum.



4.2 Posology And Method Of Administration



Adults and the Elderly



Scholl Advance Athlete's Foot Cream is applied once or twice daily to the affected skin and surrounding area in a thin layer and rubbed in gently. Before application the affected skin areas should be cleansed and dried thoroughly. In the case of intertriginous infections (interdigital, intergluteal, inguinal) the application may be covered with a gauze strip, especially at night.



Duration of treatment is one week for tinea pedis. Relief of symptoms usually occurs within a few days. Irregular use or premature discontinuation of treatment carries the risk of recurrence. If there are no signs of improvement after two weeks, the diagnosis should be verified by a physician.



Children



The experience with terbinafine cream in children is limited. Therefore, its use in children under 16 years cannot be recommended.



Method of administration



Topical administration



4.3 Contraindications



Hypersensitivity to terbinafine or any of the excipients in the cream



4.4 Special Warnings And Precautions For Use



This product is for external use only. Contact with the eyes should be avoided.



This product contains cetyl alcohol and stearyl alcohol, which may cause local skin reactions (e.g. contact dermatitis)



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



There are no known drug interactions with terbinafine cream.



4.6 Pregnancy And Lactation



Foetal toxicity and fertility studies suggest no adverse effects.



There is no clinical experience with terbinafine cream in pregnant women. Therefore, unless the potential benefits outweigh any potential risks, Scholl Advance Athlete's Foot Cream should not be administered during pregnancy.



Terbinafine is excreted in breast milk and therefore breast-feeding mothers should not use Scholl Advance Athlete's Foot Cream.



4.7 Effects On Ability To Drive And Use Machines



None known



4.8 Undesirable Effects



Occasionally, redness, itching or stinging occur at the site of application: However, treatment rarely has to be discontinued for this reason. This must be distinguished from allergic reactions, which occur rarely but require discontinuation.



4.9 Overdose



No adverse events in relation to ingestion of terbinafine cream have been reported to date. However, if accidental ingestion occurs, gastric emptying may be used if considered appropriate. Adverse reactions similar to those possible after oral administration of terbinafine tablets (e.g. headache, nausea, dizziness and upper gastrointestinal complaints) may occur following accidental ingestion of the cream.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Pharmacotherapeutic group: Terbinafine, ATC code: D01A E15



Terbinafine is an allylamine which has a broad spectrum of antifungal activity. At low concentrations, terbinafine is fungicidal against dermatophytes, moulds and certain dimorphic fungi.



The treatment effect of terbinafine is long-lasting: Less than 10% of patients suffering from tinea pedis and treated with terbinafine 1% cream for one week experienced a relapse or reinfection within three months after start of treatment.



Terbinafine interferes specifically with fungal sterol biosynthesis at an early step. This leads to a deficiency in ergosterol and to an intracellular accumulation of squalene, resulting in fungal cell death. Terbinafine acts by inhibition of squalene epoxidase in the fungal cell membrane.



The enzyme squalene epoxidase is not linked to the cytochrome P450 system. Terbinafine does not influence the metabolism of hormones or other drug substances.



5.2 Pharmacokinetic Properties



Less than 5% of the dose is absorbed after topical application to humans; systemic exposure is therefore very slight



5.3 Preclinical Safety Data



There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SmPC.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Sodium hydroxide



Benzyl alcohol



Sorbitan stearate



Cetyl palmitate



Cetyl alcohol



Stearyl alcohol



Polysorbate 60



Isopropyl myristrate



Purified water



6.2 Incompatibilities



None known



6.3 Shelf Life



2 years



6.4 Special Precautions For Storage



None.



6.5 Nature And Contents Of Container



Aluminium tube with tamper-evident membrane seal, internal lacquer coating and HDPE screw cap containing 7.5g or 15g of cream



6.6 Special Precautions For Disposal And Other Handling



Not applicable.



7. Marketing Authorisation Holder



Scholl Consumer Products Ltd.



Venus



1 Old Park Lane



Trafford Park



Manchester



M41 7HA



8. Marketing Authorisation Number(S)



PL 00587/0242



9. Date Of First Authorisation/Renewal Of The Authorisation



15/02/07



10. Date Of Revision Of The Text



17/08/07




No comments:

Post a Comment